APAC's Pioneering Role in Genetic Modification

The Asia-Pacific (APAC) region stands at the forefront of genetic modification research and application, driven by its burgeoning scientific capabilities, diverse agricultural landscapes, and pressing healthcare needs.

Life Sciences Review | Thursday, March 20, 2025

APAC leads in genetic modification, advancing GM crops, CRISPR, and animal engineering while facing ethical challenges in food security, human enhancement, and biodiversity. Responsible innovation hinges on robust regulation, public engagement, and equitable technology access.

FREMONT, CA: The Asia-Pacific (APAC) region stands at the forefront of genetic modification research and application, driven by its burgeoning scientific capabilities, diverse agricultural landscapes, and pressing healthcare needs. However, this rapid advancement necessitates a robust ethical framework to navigate the complex implications of altering the genetic code of living organisms.

The Landscape of Genetic Modification in APAC

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Agricultural Biotechnology

Countries like China, India, and Australia are at the forefront of developing and deploying genetically modified (GM) crops. These modifications enhance yield, improve pest resistance, and boost nutritional value, contributing to food security. Key crops such as rice, cotton, and soybeans are the primary focus of genetic research, with traits like drought tolerance and increased vitamin content receiving significant attention. However, the adoption of GM crops varies widely across the region, influenced by public perception, regulatory policies, and economic factors.

Human Genetic Modification

Advancements in gene editing technologies, particularly CRISPR-Cas9, are progressing rapidly in several APAC countries, including China, South Korea, and Japan. These innovations hold immense potential for treating genetic disorders and enhancing human capabilities but also raise profound ethical concerns. As gene editing blurs the line between therapeutic interventions and human enhancement, discussions on bioethics, safety, and societal impact continue to intensify.

Animal Genetic Modification

Genetic engineering is also being applied to animals in biomedical research, agriculture, and conservation. Examples include genetically modified pigs for organ transplantation and fish engineered for accelerated growth rates. While these advancements offer promising solutions, ethical concerns surrounding animal welfare and the potential ecological consequences of modified species escaping into natural environments remain significant.

Key Ethical Considerations

Food Security and Environmental Impact

While GM crops present solutions for food security, concerns persist regarding their long-term environmental effects, such as biodiversity loss and the emergence of herbicide-resistant weeds. Additionally, ensuring equitable distribution of the benefits and risks associated with GM technology is critical, particularly for smallholder farmers in developing countries. The use of gene drives—mechanisms that enable the rapid spread of genetic modifications within a species—also necessitates careful risk assessment and containment strategies.

Human Genetic Modification and Enhancement

Gene editing holds undeniable potential for treating genetic diseases, but ethical dilemmas arise when the line between therapy and human enhancement becomes blurred. Concerns regarding the possibility of “designer babies” and the exacerbation of social inequalities through genetic enhancement are particularly pressing. Furthermore, the long-term safety of gene editing technologies remains uncertain, necessitating a cautious and regulated approach.

Animal Welfare and Ecological Impacts

Genetic modification of animals raises concerns about their well-being, particularly regarding potential pain and suffering during the modification process. Moreover, introducing genetically altered species into natural ecosystems could have unintended ecological consequences, such as disrupting biodiversity or creating invasive species. The ethical implications of using genetically modified animals as organ donors for humans also require careful deliberation.

Regulatory Frameworks and Public Engagement

Robust regulatory frameworks are essential to ensure responsible innovation in genetic modification. However, harmonizing regulations across the highly diverse APAC region remains a challenge. Public engagement and transparent dialogue are equally crucial for building trust, addressing ethical concerns, and fostering informed decision-making. Additionally, cultural and religious values significantly shape public perceptions of genetic modification, further influencing policy development.

Intellectual Property and Access

The patenting of genetically modified organisms (GMOs) and gene-editing technologies raises concerns about accessibility and affordability, particularly in developing countries. Equitable access to the benefits of genetic modification is vital for addressing global health and food security challenges. Striking a balance between intellectual property rights and widespread access to these technologies is a critical issue that requires careful policy consideration.

Balancing Innovation and Responsibility

Strengthening regulatory frameworks is essential, requiring comprehensive policies that address both the risks and benefits of genetic modification technologies. Independent ethics committees should be established to review research proposals and ensure compliance with ethical standards, while international collaboration can help harmonize regulatory standards across the region. Equally important is promoting public engagement and education through open discussions on the moral implications of genetic modification, providing accessible and accurate information to dispel misconceptions, and integrating ethical considerations into science education curricula. Investing in ethical research is crucial, supporting interdisciplinary studies on genetic modification's legal, social, and moral impacts while developing frameworks to assess long-term consequences. Encouraging collaboration between scientists, ethicists, and policymakers will further guide responsible research.

Additionally, ensuring responsible innovation requires prioritizing research emphasizing safety, sustainability, and equitable access while exploring alternative technologies that address similar challenges with fewer ethical concerns. Implementing strong biosafety and biosecurity measures will be critical in preventing unintended consequences. By adopting these strategies, APAC nations can achieve responsible advancements in genetic modification while maintaining ethical integrity and societal trust.

The APAC region can potentially lead the world in responsible innovation in genetic modification. By prioritizing ethical considerations and fostering open dialogue, APAC nations can ensure that the benefits of this powerful technology are harnessed for the betterment of humanity and the planet.

More in News

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Inventus welcomes senior figure from Google as a board adviser

Autologous and Allogeneic Models Push Cell Therapy Toward Different Development Paths

Cell therapy product development is becoming more segmented as autologous and allogeneic products place different demands on design, manufacturing and commercialization. Developers can no longer discuss the sector as one uniform category. Product strategy depends heavily on whether cells come from the patient or from a donor source. Autologous therapies are often built around individualized production. A patient’s own cells are collected, processed and returned as a therapy. This model can create a strong biological fit, but it also places pressure on scheduling, chain of identity, release timelines and site coordination. Every patient-specific batch becomes both a treatment and a manufacturing event. Allogeneic therapies take a different approach. Instead of using each patient's own cells, they rely on donor-derived or engineered cells that can be produced in larger batches and supplied to more patients. This model has the potential to improve access and make therapies more widely available, provided quality, immune compatibility and long-term performance are carefully managed. At the same time, it brings its own set of challenges, including how cells are sourced, how consistently they can be expanded during manufacturing, how they are stored and how different patients may respond to the treatment. Industry analysis from Thermo Fisher Scientific’s Patheon unit notes that autologous therapies require individualized handling because each treatment is tailored to a patient’s cells, while allogeneic therapies must ensure consistent quality and address immune compatibility across recipients. These differences influence product development from the very beginning. For autologous therapies, developers often concentrate on coordinating the entire vein-to-vein process, including logistics, site readiness, rapid release testing and making sure each patient's cells move through the system efficiently. Developers of allogeneic therapies face a different set of priorities, with greater attention on master cell banks, consistency between production batches, inventory management and large-scale quality control. Each approach comes with its own operational challenges, costs and risks that need to be managed throughout development. Manufacturing partners are therefore becoming more specialized. A partner supporting allogeneic production may need scale-up expertise and robust batch release processes. Developers must choose partners based on model fit, not general cell therapy experience alone. Digital systems are becoming important in both pathways. Developers need data continuity from cell collection through manufacturing and administration. Gaps in records can create delays and weaken confidence. Better data handling can support quality review and long-term learning across batches or patient cases. The future of cell therapy product development will likely involve both models advancing in parallel. Autologous and allogeneic approaches solve different problems and face different barriers. The companies best positioned will be those that align biology, manufacturing design, clinical planning and commercial delivery around the specific therapy model they are building. ...Read more

Specials

APAC's Pioneering Role in Genetic Modification

The Asia-Pacific (APAC) region stands at the forefront of genetic modification research and application, driven by its burgeoning scientific capabilities, diverse agricultural landscapes, and pressing healthcare needs.